These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 18204222)

  • 21. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
    Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
    J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclosporin A inhibits nucleotide excision repair via downregulation of the xeroderma pigmentosum group A and G proteins, which is mediated by calcineurin inhibition.
    Kuschal C; Thoms KM; Boeckmann L; Laspe P; Apel A; Schön MP; Emmert S
    Exp Dermatol; 2011 Oct; 20(10):795-9. PubMed ID: 21707758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between DNA repair gene XPD751 single-nucleotide polymorphisms and prognosis of colorectal cancer.
    Dong Y; Liu JW; Gao YJ; Zhou T; Chen YM
    Genet Mol Res; 2015 May; 14(2):5390-8. PubMed ID: 26125734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
    Fleming ND; Agadjanian H; Nassanian H; Miller CW; Orsulic S; Karlan BY; Walsh CS
    Cancer; 2012 Feb; 118(3):689-97. PubMed ID: 21751198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis.
    Li C; Hu Z; Liu Z; Wang LE; Strom SS; Gershenwald JE; Lee JE; Ross MI; Mansfield PF; Cormier JN; Prieto VG; Duvic M; Grimm EA; Wei Q
    Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2526-32. PubMed ID: 17164380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of XPC, XPD, XPF, and XPG gene polymorphisms on the risk and the outcome of acute myeloid leukemia in a Romanian population.
    Bănescu C; Iancu M; Trifa AP; Dobreanu M; Moldovan VG; Duicu C; Tripon F; Crauciuc A; Skypnyk C; Bogliș A; Lazar E
    Tumour Biol; 2016 Jul; 37(7):9357-66. PubMed ID: 26779634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.
    Park DJ; Zhang W; Stoehlmacher J; Tsao-Wei D; Groshen S; Gil J; Yun J; Sones E; Mallik N; Lenz HJ
    Clin Adv Hematol Oncol; 2003 Mar; 1(3):162-6. PubMed ID: 16224397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients.
    Saldivar JS; Lu KH; Liang D; Gu J; Huang M; Vlastos AT; Follen M; Wu X
    Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S223-9. PubMed ID: 17825393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Variants in nucleotide excision repair core genes and susceptibility to recurrence of squamous cell carcinoma of the oropharynx.
    Song X; Sturgis EM; Jin L; Wang Z; Wei Q; Li G
    Int J Cancer; 2013 Aug; 133(3):695-704. PubMed ID: 23335232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
    Huang MY; Tsai HL; Lin CH; Huang CW; Ma CJ; Huang CM; Chai CY; Wang JY
    J Surg Oncol; 2013 Dec; 108(7):457-64. PubMed ID: 23996617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk Modulation of Oral Pre Cancer and Cancer with Polymorphisms in XPD and XPG Genes in North Indian Population.
    Nigam K; Yadav SK; Samadi FM; Bhatt ML; Gupta S; Sanyal S
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2397-2403. PubMed ID: 31450912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single nucleotide polymorphisms and clinical outcome in patients with biliary tract carcinoma treated with epirubicin, cisplatin and capecitabine.
    Pacetti P; Giovannetti E; Mambrini A; Nannizzi S; Orlandi M; Tartarini R; Del Freo A; Del Tacca M; Danesi R; Cantore M
    Anticancer Res; 2009 May; 29(5):1835-40. PubMed ID: 19443413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SNP-SNP interactions between DNA repair genes were associated with breast cancer risk in a Korean population.
    Han W; Kim KY; Yang SJ; Noh DY; Kang D; Kwack K
    Cancer; 2012 Feb; 118(3):594-602. PubMed ID: 21751184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. XPG rs2296147 T>C polymorphism predicted clinical outcome in colorectal cancer.
    Wang F; Zhang SD; Xu HM; Zhu JH; Hua RX; Xue WQ; Li XZ; Wang TM; He J; Jia WH
    Oncotarget; 2016 Mar; 7(10):11724-32. PubMed ID: 26887052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive impact of genetic polymorphisms in DNA repair genes on susceptibility and therapeutic outcomes to colorectal cancer patients.
    Sun K; Gong A; Liang P
    Tumour Biol; 2015 Mar; 36(3):1549-59. PubMed ID: 25355595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin.
    Kim JG; Chae YS; Sohn SK; Moon JH; Ryoo HM; Bae SH; Kum Y; Jeon SW; Lim KH; Kang BM; Park IJ; Choi GS; Jun SH
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):953-60. PubMed ID: 19219602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI.
    Seo BG; Kwon HC; Oh SY; Lee S; Kim SG; Kim SH; Han H; Kim HJ
    Oncol Rep; 2009 Jul; 22(1):127-36. PubMed ID: 19513514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer.
    Chen J; Xie F; Chen K; Wang D; Jiang H; Li J; Pan F; Chen S; Zhang Y; Ruan Z; Huang H; Zou L; Liang H
    Cancer Biol Ther; 2009 Jul; 8(14):1424-30. PubMed ID: 19458483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer.
    Gu J; Zhao H; Dinney CP; Zhu Y; Leibovici D; Bermejo CE; Grossman HB; Wu X
    Clin Cancer Res; 2005 Feb; 11(4):1408-15. PubMed ID: 15746040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.